<DOC>
	<DOCNO>NCT00000652</DOCNO>
	<brief_summary>To assess safety tolerance combination zidovudine ( AZT ) didanosine ( ddI ) child HIV infection . New approach use available agent may provide increase improved treatment option AIDS . Combination therapy expect play major role improve survival quality life HIV-infected individual . AZT ddI two agent extensively evaluate evidence antiretroviral effectiveness strong .</brief_summary>
	<brief_title>A Phase I Study Evaluate Safety Toxicity Combination Zidovudine 2',3'-Dideoxyinosine ( Didanosine ) Children With HIV Infection</brief_title>
	<detailed_description>New approach use available agent may provide increase improved treatment option AIDS . Combination therapy expect play major role improve survival quality life HIV-infected individual . AZT ddI two agent extensively evaluate evidence antiretroviral effectiveness strong . Patients take AZT ddI empty stomach ; ddI take 2 minute take antacid . Part A patient receive AZT plus ddI ranging dos . Patients part B may receive high dose ddI patient part A . The first patient enrol give low dose . Subsequent patient receive increasingly high dos dose limit toxicity occurs .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Corticosteroids treatment lymphocytic interstitial pneumonitis . Concurrent Treatment : Allowed : Intravenous hyperalimentation . Patients must follow : P2 class symptomatic HIV infection define CDC OR asymptomatic whose total CD4 cell count &lt; 500 cells/mm3 . Freedom significant active opportunistic infection require specific therapy . Part B patient : Prior treatment zidovudine ( AZT ) discontinue hematologic toxicity . Availability parent legal guardian sufficiently reliable give inform consent follow necessary study procedure include administration medication return followup visit . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Critically ill , clinically unstable , receive drug therapy opportunistic infection . History acute chronic pancreatitis . Patients follow exclude : Critically ill , clinically unstable , receive drug therapy opportunistic infection . History acute chronic pancreatitis . Prior Medication : Excluded : Antiretroviral antiviral agent within 14 day entry study . Immunomodulating agent , cytolytic chemotherapeutic agent , corticosteroid within 30 day ( except lymphocytic interstitial pneumonitis ) . Part A patient : Zidovudine ( AZT ) didanosine ( ddI ) . Part B patient : Didanosine ( ddI ) . Prior Treatment : Excluded : Radiation therapy within 30 day . Intravenous immunoglobulin preparation within 14 day entry study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
</DOC>